News

MC “Comac Medical” receives NAI Letter from the FDA

After successfully passing a pre-approval FDA inspection, Comac Medical’s Clinical Research Unit has been honored with a NAI certificate.

The scheduled US FDA visit lasted 5 days – between 10th and 14th of February 2020. During the inspection, the Clinical Research Unit was checked for compliance with the US FDA requirements. The inspection included extensive review of documentation, and no FDA Form 483 has been issued.

After the inspection, the FDA determined that the areas evaluated are in compliance with applicable laws and regulations. The FDA and the Inspection Classification Database classified the inspection with NAI, which means no objectionable conditions or practices were found during the inspection (or the objectionable conditions found do not justify further regulatory action).

“Thank you all for doing a fantastic job!”, commented the Vice-President of the Sponsor of the inspected study, congratulating the whole Comac Medical team.

The blinded NAI Letter can be obtained from the  Certifications page  on the Comac Medical website.

 

Share:
In today’s fast-evolving biotech landscape, choosing the right biotech CRO (Contract Research Organization) can be the single most...
[Sofia, Bulgaria] – Comac Medical is pleased to announce that Steve Angus will be joining Comac Medical as...
Summer brings sunlit days, long evenings, and countless opportunities to enjoy the outdoors. Yet for the pharmaceutical and...